The most recent disclosure that Godsey & Gibb INC has made with the Securities and Exchange Commission (SEC) indicates that the company purchased a new holding in Teleflex Incorporated (NYSE: TFX) during the fourth quarter of the company.
The corporation shelled out nearly two hundred and fifty thousand dollars to purchase one thousand shares of ownership in the medical technology startup.
Several hedge funds have recently made a variety of shifts to their positions in the company in response to recent developments.
The purchase of stock in Teleflex by Ronald Blue Trust INC cost the company $34,000 during the year’s second quarter.
During the final three months of 2018, General Partner, INC invested $28,000 worth of capital in Teleflex stock.
This investment was valued at $28,000.
During the third quarter, Lazard Asset Management LLC completed a 900% increase in Teleflex stock held in its portfolio. Since the beginning of the most recent quarter, Lazard Asset Management LLC has acquired an additional 180 shares of the medical technology company’s stock, bringing the total number of shares it owns to 182, with a value of $36,000.
These shares were formerly held in the company’s possession.
During the third quarter of the current fiscal year, Wipfli Financial Advisors LLC invested in Teleflex shares worth $55,000.
Last but not least, during the final three months of 2018, Romano Brothers & Company spent $69,000 to acquire an additional position in Teleflex.
Most of the company’s stock is owned by institutional investors and hedge funds, which account for 93.82% of the total.
Recent years have seen a proliferation of research articles that have focused their attention on TFX. Stephens raised their target price for the stock from $280.00 to $295.00 and upgraded Teleflex from an “underweight” rating to an “equal weight” rating in a research report published on Wednesday, December 28.
In a research note published on Monday, February 27, Truist Financial assigned Teleflex a “hold” rating and lowered their target price on Teleflex stock from $260.00 to $250.00.
Both of these changes were made to the company’s stock.
In addition to that, they provided the company with a recommendation of “hold.” The rating for Teleflex at Morgan Stanley was upgraded from “equal weight” to “overweight” in a research note published on Friday, January 6.
Additionally, they increased the price target they had set for the stock from $236.00 to $280.00. Raymond James upgraded Teleflex from an “outperform” rating to a “strong-buy” rating and increased their target price on the stock from $231.00 to $259.00 in a research note published on Friday, February 24.
Last, StockNews.com shifted its recommendation for Teleflex from “hold” to “buy” in a research report published on Wednesday. Seven market researchers have suggested that investors buy company shares, while six have stated that investors should keep their holdings the same.
The information on Bloomberg.com indicates that the company has been given an average “Moderate Buy” recommendation, and its target price has been set at $271.69.
The price of a share of Teleflex rose $3.85 during the morning session on Friday, bringing it to a new all-time high of $245.19.
In comparison to the stock’s average volume of 349,639 shares traded, there were 73,118 transactions of the stock’s shares.
The company’s current price, which is trading at $240.27, is higher than its 50-day simple moving average, which is $229.76.
The price-to-earnings ratio for the company is 31.42; the price-to-earnings-to-growth ratio is 2.57; and the beta value for the company is 0.98.
It is currently worth a total of $11.51 billion.
The price at which Teleflex Incorporated reached its 12-month low was $182.65, while the price at which the company reached its 12-month high was $356.72.
The values displayed are a debt-to-equity ratio of 0.40, a current ratio of 2.43, and a quick ratio of 1.43.
On Thursday, February 23, Teleflex’s most recent quarterly earnings report (NYSE: TFX) was made public for publication.
The company that makes medical technology announced that it made $3.52 in profits for the quarter, which is $0.08 more than the average estimate made by analysts, which was $3.44.
The company’s sales for the quarter came in at $758 million, which is lower than the industry professionals’ forecasts of $760.29 million provided by the company.
The return on equity for the company was 15.87%, and its net margin was 13.01%.
Teleflex experienced a decline in revenue of 5% when compared to the same quarter in the previous year, 2017.
The company reported a profit of $3.60 per share during the same period in the previous year’s financial statements. Sell-side analysts forecast that the current fiscal year will bring in 13.29 cents per share for Teleflex Corporation.
In addition, the business recently announced and proceeded with the distribution of a quarterly dividend, which took place on March 15 of this year. On Friday, March 3, shareholders who still owned their shares as of the previous business day were eligible to receive a $0.34 dividend payment.
The annualized calculation suggests that this translates to a dividend payment of $1.36 and a yield of 0.55%.
The day that dividends were supposed to be paid out was last Thursday, March 2.
The percentage of profits distributed as dividends by Teleflex Corporation comes in at 17.71%.
The medical technology that is produced by Teleflex, INC assists professionals working in the healthcare industry in their efforts to improve the outcomes for patients while simultaneously improving the safety of both the providers and the patients.
The company is in the business of designing, developing, manufacturing, and selling one-time-use medical devices.
These devices are used in hospitals and other healthcare institutions for critical care and surgical procedures.